Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

188 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Screen Failure Form

- 28/11/2018 - 1 Formulário, 1 Grupo de itens, 3 Elementos de dados, 1 Idioma
Grupo de itens: Screen Failure Data
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 - Eligibility

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 27 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00640016

Eligibility Asthma NCT00393952

- 11/04/2016 - 1 Formulário, 3 Grupos de itens, 19 Elementos de dados, 1 Idioma
Grupos de itens: Criteria, Inclusion Criteria, Exclusion Criteria
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00393952

Eligibility Asthma NCT00181285

- 05/04/2016 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT); ODM derived from: https://clinicaltrials.gov/show/NCT00181285

Eligibility Asthma NCT00351143

- 07/04/2016 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control; ODM derived from: https://clinicaltrials.gov/show/NCT00351143

Eligibility Asthma NCT00384813

- 27/09/2021 - 1 Formulário, 2 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00384813

Eligibility Asthma NCT00320034

- 27/09/2021 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00320034

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Eligibility Criteria

- 27/09/2021 - 1 Formulário, 3 Grupos de itens, 30 Elementos de dados, 1 Idioma
Grupos de itens: Eligibility Question, Inclusion Criteria, Exclusion Criteria
Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Eligibility Criteria.

Eligibility Asthma NCT00288379

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00288379

Eligibility Allergic NCT00836368

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics; ODM derived from: https://clinicaltrials.gov/show/NCT00836368

Eligibility Asthma NCT01435902

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise; ODM derived from: https://clinicaltrials.gov/show/NCT01435902

Eligibility Asthma NCT00658749

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 21 Elementos de dados, 1 Idioma
Grupo de itens: Criteria
A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00658749

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial